|
Klaassen rule
|
|
|
|
|
|
|
|
|
Klaassen
[24] (derivation) |
140 |
227 |
Median 6.8 y (range 6 m to 17 y: derivation set) |
Significant bacterial infection |
37% |
87.5% (95% CI 76.4% to 93.8%) |
41.2% (95% CI 35.9% to 46.6%) |
| Amman [7]
|
206 |
423 |
6.9 years (IQR 3.8 years to 11.6 years) |
Serious adverse medical outcome |
38% |
86.9% (95% CI 79.8% to 91.8%) |
48.5% (95% CI 42.9% to 54.1%) |
| Macher [20]
|
167 |
377 |
Median 6 y, range7 m to 19 y |
Significant bacterial infection |
40% |
79.3% (95% CI 61.6% to 90.2%) |
45% (95% CI 35.9% to 54.3%) |
| Baorto [22]
|
558 |
1171 |
Mean 8.0 y (range 1 y to 23 y) |
Bacteraemia |
21% |
88.9% (95% CI 83.6% to 92.6%) |
22.4% (95% CI 19.9% to 25.1%) |
| Madsen [23]
|
76 |
157 |
Mean 8 y (range 2 m to 18 y) |
Microbiologically documented infection |
39% |
91.7% (95% CI 74.2% to 97.7%) |
41% (95% CI 35.5% to 46.8%) |
| Rackoff [21]
|
72 |
172 |
Range 9 m to 18 y: derivation set |
Bacteraemia |
19% |
100% (95% CI 89.8% to 100%) |
23.2% (95% CI 16.9% to 30.9%) |
|
Ammann 2003 rule
|
|
|
|
|
|
|
|
|
Ammann
[32] (derivation) |
132 |
364 |
Not reported |
Severe bacterial infection |
14% |
100% (95% CI 95.9% to 100%) |
22.7% (95% CI 16.8% to 30%) |
| SPOG [7]
|
206 |
423 |
6.9 years (IQR 3.8 years to 11.6 years) |
Severe bacterial infection |
10% |
96.7% (95% CI 91.9% to 98.7%) |
12.3% (95% CI 9.1% to 16.5%) |
| Macher [20]
|
167 |
377 |
Median 6 y, range7 m to 19 y |
Severe bacterial infection |
8% |
95.2% (95% CI 86.9% to 98.4%) |
9.1% (95% CI 6.4% to 12.8%) |
|
Alexander rule
|
|
|
|
|
|
|
|
|
Alexander
[28] (derivation) |
104 |
188 |
Mean 8.9 y, SD 5.7 |
Adverse medical complication |
58% |
84.6% (95% CI 57.8% to 95.7%) |
64.6% (95% CI 53.8% to 74.1%) |
| SPOG [7]
|
206 |
423 |
6.9 years (IQR 3.8 years to 11.6 years) |
Adverse medical complication |
8% |
94.3% (95% CI 88.6% to 97.2%) |
8.6% (95% CI 6% to 12.4%) |
| Dommett [2]
|
368 |
762 |
Median age 5 years 7 months (range 1 month to 17 years 6 months). |
Adverse medical complication |
53% |
58.7% (95% CI 52.2% to 65%) |
57.9% (95% CI 53.7% to 62%) |
|
Programa Infantil Nacional de Drogas Antineoplásticas (PINDA) Rule
|
|
|
|
|
|
|
|
|
Santolaya (derivation) [26]
|
257 |
447 |
Mean 7 y (range 6 m to 18 y) |
Invasive bacterial infection |
43% |
85.4% (95% CI 79.5% to 89.8%) |
64.6% (95% CI 58.2% to 70.5%) |
| Santolaya (validation) [25]
|
170 |
263 |
Mean 7 y (range 7 m to 17 y) |
Invasive bacterial infection |
40% |
92.1% (95% CI 86.5% to 95.6%) |
76.4% (95% CI 68.2% to 83.1%) |
| SPOG [7]
|
206 |
423 |
6.9 years (IQR 3.8 years to 11.6 years) |
Invasive bacterial infection |
15% |
93.4% (95% CI 87.6% to 96.6%) |
18.9% (95% CI 14.9% to 23.7%) |
| Macher [20]
|
167 |
377 |
Median 6 y, range7 m to 19 y |
Invasive bacterial infection |
46% |
66.7% (95% CI 51% to 79.4%) |
48.1% (95% CI 41.4% to 54.8%) |
|
Swiss Pediatric Oncology Group (SPOG) 2010 Rule
|
|
|
|
|
|
|
|
|
SPOG
[7] (Adverse events rule derivation) |
206 |
423 |
6.9 years (IQR 3.8 years to 11.6 years) |
Serious adverse medical outcome |
35% |
92% (IQR 91% to 93%, range 90% to 98%) |
45% (IQR, 38% to 49%, range 12% to 57%) |
| Miedeima [19]
|
110 |
210 |
Median 6.6 years (IQR 4.3 years to 10.8 years) |
Serious adverse medical outcome |
50% |
82% (95% CI, 77% to 87% |
57% (95% CI, 50% to 64%) |
|
Rondinelli Rule
[27]
(no derivation data)
|
|
|
|
|
|
|
|
| Macher [20]
|
167 |
377 |
Median 6 y, range7 m to 19 y |
Severe bacterial infection |
N/A |
62% (36–82) |
43% (34–52) |
| SPOG [7]
|
206 |
423 |
6.9 years (IQR 3.8 years to 11.6 years) |
Severe bacterial infection |
35% |
84.4% (95% CI 77% to 89.8%) |
43.2% (95% CI 37.7% to 48.8%) |
